DanaRizk University of Alabama at BirminghamUnited States

DanaRizk
Dr Dana Rizk is Tenured Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB). She also serves as Director of Clinical Trials Research in the Division of Nephrology and as Medical Director for the Clinical Trials Administrative Office (part of the CCTS) at UAB. She has a passion for education and has served as a member of the Clinical Competency Committees for the Internal Medicine as well as the Nephrology Programs. She is the recipient of several teaching awards. Her clinical and research interests revolve around glomerular diseases and, in particular IgA Nephropathy (IgAN). She has served as the site principal investigator on many clinical trials and is part of several multi-disciplinary translational research projects focused on the role of biomarkers in the diagnosis and prognosis of IgAN. Her research efforts have resulted in more than 60 peer-reviewed publications in prestigious medical journals including the New England Journal of Medicine.
Institution

Day 2 - Monday April 15, 2024

Time Session
3 p.m.
4 p.m.
Late Breaking Clinical Trials Session
AlessiaFornoni Chairperson afornoni@med.miami.eduUnited States
MichelleRheault Chairperson rheau002@umn.eduUniversity of MinnesotaUnited States
  • Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
    PietroRavani Free Communication pravani@ucalgary.caUniversity of CalgaryCanada
  • Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas – Recommendations and Updates
    Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research ConsultantDenmark
  • EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
    DanaRizk Free Communication drizk@uabmc.eduUniversity of Alabama at BirminghamUnited States
  • SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
    JonathanBarratt Free Communication jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
  • PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
    CécileCouchoud Free Communication cecile.couchoud@biomedecine.frREIN registry, Agence de la biomédecine, FranceFrance
Hall A

Pre-Congress - Saturday April 13, 2024

Time Session
9 a.m.
11 a.m.
Primer Course in Glomerular Disease: A Case-Based Approach: Foundation in Glomerular Diseases & Rapidly Progressive Glomerulonephritis
AdrianLiew Chairperson draliew2@gmail.comMount Elizabeth Novena Hospital, SingaporeSingapore
HeatherReich Chairperson Heather.Reich@uhn.caUniversity of Toronto, University Health NetworkCanada
HernánTrimarchi Chairperson htrimarchi@hotmail.comHOSPITAL BRITÁNICO DE BUENOS AIRESArgentina
JonathanBarratt Chairperson jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
  • Histophysiology of the Glomerulus
    SoniaChicano Speaker sonialchicano@yahoo.comISNPhilippines
  • Overview of Immunosuppression
    DanaRizk Speaker drizk@uabmc.eduUniversity of Alabama at BirminghamUnited States
  • Genetic Testing in Glomerular Diseases
    KeishaGibson Speaker keisha_gibson@med.unc.eduUniversity of North Carolina at Chapel Hill, USAUnited States
  • Approach to RPGN
    ArennJauhal Speaker Arenn.Jauhal@uhn.caCanada
  • Case Presentation and Discussion 1
    HernánTrimarchi Speaker htrimarchi@hotmail.comHOSPITAL BRITÁNICO DE BUENOS AIRESArgentina
Hall E